Skip to content

Demonstration of Carbonyl Stress on Hair Follicles

Demonstration of the Presence of Carbonyl Stress in the Hair Follicles of Women With Reactive Hair Loss

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03414476
Enrollment
40
Registered
2018-01-30
Start date
2018-03-26
Completion date
2018-06-25
Last updated
2020-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Effluvium; Telogen

Brief summary

In this study, the investigator will try to highlight the presence of carbonyl compounds in the hair follicles of women with telogen effluvium (ET) linked to stress of various origins (fatigue, infectious diseases, emotional stress ...).

Detailed description

At the cutaneous level, oxidative stress induces the formation of carbonyl compounds which, by binding to proteins, produce nonfunctional adducts inducing cutaneous aging. Is this mechanism, called Carbonyl stress, also present in the scalp and can it be one of the mechanisms involved in the occurrence of reactive hair loss ? To demonstrate this, samples of hair follicles are made. The proteins are extracted from the samples and then assayed. The oxidized (carbonyl) proteins are labeled with specific fluorescent probes.

Interventions

The follicles will be collected by lock of 10 hair on the scalp (centro-parietal part), to obtain 40 follicles with epithelial sheath

Sponsors

Pierre Fabre Dermo Cosmetique
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Masking description

Monocentric, Exploratory study, open, comparative, in parallel groups

Intervention model description

1 group of women with effluvium télogène 1 group of women without effluvium télogène

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

Criteria related to the Population : * Women aged from 18 to 40 ans (included) * Phototype I à IV included, according to Fitzpatrick Classification * Hair length 5 cm on the sampling area (centro-parietal part) * Last shampoo at least 2 days before the inclusion visit, without application of styling product, care or water between this last shampoo and the inclusion * Informed consent signature Criteria related to the studied condition: * ET group: hair loss related to various etiologies evaluated by a questionnaire according to the investigator's opinion and positive pull test (at least 3 hair collected per lock of 50 to 60 hair) AND * Control group : no hair loss, evaluated by the questionnaire and negative pull test (less than 3 hair collected per lock of 50 to 60 hair)

Exclusion criteria

Criteria related to Population : * Menopause * Pregnancy, breastfeeding, childbirth for less than 6 months Criteria related to Pathology : For both groups: * Alopecia causing hair loss on the upper part of the scalp * Dermatological pathology or evolving cutaneous lesion in the scalp * Control group only: * Chronic unstabilized condition * Acute evolving pathology Criteria related to theTreatments : For both groups: * Use for at least 1 month of Minoxidil, Aminexil in the 3 months before inclusion or ongoing * Systemic treatment affecting hair growth * Any treatment or dietary supplement for antioxidant or capillary Control group only: * Treatment of general thyroid disorders initiated or modified for less than 3 months prior to inclusion * Treatment of anemia if started less than 3 months before inclusion * General treatment initiated or modified for less than 3 months prior to inclusion in the study

Design outcomes

Primary

MeasureTime frameDescription
Biological evaluationVisit 1- Day 1Evaluation of the quantity of carbonyl compounds measured in the hair follicles taken from the two groups.

Secondary

MeasureTime frameDescription
Safety evaluationVisit 1- Day 1Adverse events evaluation

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026